California-based InSite Vision has signed its first licensing and distribution agreement outside North America for AzaSite 1 percent with South Korea’s Shin Poong Pharm.

Under the terms of the agreement, Shin Poong will obtain regulatory approval and market AzaSite (azithromycin ophthalmic solution) in Korea.

AzaSite was approved to treat bacterial conjunctivitis by the FDA in April and was launched in the U.S. by Inspire Pharmaceuticals in August.

InSite said it also has filed a new drug submission with Health Canada to market AzaSite in Canada.